コンテンツへスキップ
Merck
  • New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.

New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.

Chemical communications (Cambridge, England) (2004-07-28)
Carine Aubry, Paul R Jenkins, Sachin Mahale, Bhabatosh Chaudhuri, Jean-Didier Maréchal, Michael J Sutcliffe
要旨

The first biologically active non-planar analogues of the toxic anti-cancer agent, fascaplysin, have been produced; we present the design, synthesis and biological activity of three tryptamine derivatives.